Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo to Copromote 1st Antibody Drug with AstraZeneca
January 19, 2012
- Nexium Dominates Top 2 Rankings in HP Market 2 Months in a Row: RepTrack Dec. Survey
January 18, 2012
- AZ Appeals Effectiveness of Faslodex as Secondary Treatment
January 18, 2012
- BTMU Forecast 1% Growth in 2012 Domestic Ethical Drug Market
January 18, 2012
- Hisamitsu Starts Capital, Business Alliance with Yutoku Following Acquisition of 15% of Its Shares
January 18, 2012
- Eisai: Insomnia Treatment Lunesta Approved
January 18, 2012
- Astellas: Regnite Approved for RLS
January 18, 2012
- MSD: Cancidas Approved for Treatment of Deep Mycoses
January 18, 2012
- Otsuka: Abilify Obtains Add’l Indication for Manic Symptoms in Bipolar Disorder, OD Tablets as Well
January 18, 2012
- MSD: Rotavirus Vaccine RotaTeq Oral Solution Approved
January 18, 2012
- Nobelpharma and Eisai Launch Anticonvulsant Agent Fostoin on Jan. 17
January 17, 2012
- MTPC Licenses Hib Vaccine from Nuron Biotech
January 17, 2012
- 38% of Doctors Will Attend Company-Sponsored Events Only if Transportation, Lodging Costs Are Paid: Survey
January 17, 2012
- 100th Acquisition/License Support Agreement Reached through LSIP Fund
January 17, 2012
- MTPC Issues Apology for Its Researcher’s Arrest on Suspicion of Bodily Harm
January 16, 2012
- President Tamura Says Nichi-Iko to Stop Receiving Marketing Right Transfers of Long-Listed Products
January 16, 2012
- Market for New Oral Anticoagulants Getting Crowded
January 16, 2012
- Sales of DPP-4 Inhibitors on Track to Reach ¥100 Bil. this Fiscal Year
January 16, 2012
- With 3 New Treatments, 2011 a Big Year for Domestic AD Market
January 16, 2012
- No Clear Road to Distribution Reform; New Drug Premium Hurting Wholesalers’ Business
January 16, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…